Reclassifying No Specific Molecular Profile Endometrial Cancer: A Narrative Review of Molecular Heterogeneity, Prognostic Refinement, and Clinical Management
- 1Department of Obstetrics and Gynecology, Peking University First Hospital, Peking University Health Science Center, Beijing 100034, China
- 2Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing 100034, China
Abstract
Molecular classification has transformed the management of endometrial cancer (EC), yet the no specific molecular profile (NSMP) subtype remains a major challenge for precision oncology due to its substantial biological and clinical heterogeneity. This narrative review summarizes evidence on the molecular features, candidate prognostic biomarkers, procedural implications, and treatment data relevant to NSMP EC and proposes a conceptual framework for further study. Emerging evidence indicates that NSMP represents a heterogeneous disease spectrum rather than a uniform entity. Histological grade and estrogen receptor (ER) expression provide important prognostic refinement, while molecular alterations, including CTNNB1 mutations, ARID1A abnormalities, and L1CAM overexpression, may further discriminate risk. Current trials and guidelines increasingly support biomarker-driven treatment strategies, although prospective validation is needed. In conclusion, NSMP EC requires further refinement beyond conventional risk classification. We propose an evidence-informed three-layer conceptual framework integrating molecular classification (POLE, MMR, and p53 status), clinicopathological factors (grade and ER expression), and emerging biomarkers, including ARID1A and L1CAM. This framework is intended to organize current evidence and generate hypotheses for future validation, which may facilitate individualized prognostic assessment of NSMP EC.
Related
- Reclassifying renal cell carcinoma with pathologic lymph node metastasis: An approach to refining prognostic stratification in patients with AJCC III and IV stages
- Apparent diffusion coefficient values on MRI as biomarkers for pre operative prediction of prognostic factors in endometrial cancer
- Treatment-Free Interval as a Prognostic Factor for Survival Outcomes in Patients with Advanced or Recurrent Endometrial Cancer Treated with Pembrolizumab Plus Lenvatinib: A Multi-Institutional Real-World Cohort Study
- Beyond Molecular Classification: The Incremental Value of Prognostic Biomarkers in Endometrial Cancer
- Prognostic Significance of Amino Acid Transporters in Endometrial Cancer
BibTeX
@article{you2026reclassifying,
title = {{Reclassifying No Specific Molecular Profile Endometrial Cancer: A Narrative Review of Molecular Heterogeneity, Prognostic Refinement, and Clinical Management}},
author = {Yujing You and Yan Zhang},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18193223},
url = {https://europepmc.org/article/PMC/PMC13664198},
note = {CC BY},
}
RIS
TY - JOUR
TI - Reclassifying No Specific Molecular Profile Endometrial Cancer: A Narrative Review of Molecular Heterogeneity, Prognostic Refinement, and Clinical Management
AU - Yujing You
AU - Yan Zhang
PY - 2026
DA - 2026/10/01
JO - Cancers
DO - 10.3390/cancers18193223
UR - https://europepmc.org/article/PMC/PMC13664198
AB - Molecular classification has transformed the management of endometrial cancer (EC), yet the no specific molecular profile (NSMP) subtype remains a major challenge for precision oncology due to its substantial biological and clinical heterogeneity. This narrative review summarizes evidence on the molecular features, candidate prognostic biomarkers, procedural implications, and treatment data relevant to NSMP EC and proposes a conceptual framework for further study. Emerging evidence indicates that NSMP represents a heterogeneous disease spectrum rather than a uniform entity. Histological grade and estrogen receptor (ER) expression provide important prognostic refinement, while molecular alterations, including CTNNB1 mutations, ARID1A abnormalities, and L1CAM overexpression, may further discriminate risk. Current trials and guidelines increasingly support biomarker-driven treatment strategies, although prospective validation is needed. In conclusion, NSMP EC requires further refinement beyond conventional risk classification. We propose an evidence-informed three-layer conceptual framework integrating molecular classification (POLE, MMR, and p53 status), clinicopathological factors (grade and ER expression), and emerging biomarkers, including ARID1A and L1CAM. This framework is intended to organize current evidence and generate hypotheses for future validation, which may facilitate individualized prognostic assessment of NSMP EC.
SN - 2072-6694
ER -